A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial

Krystal Bergin, Flora Yuen, Craig Wallington-Beddoe, Anna Kalff, Shreerang Sirdesai, John Reynolds, Andrew Spencer

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences